The balm of gilead: Is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation?

Must treatment be provided to subjects who acquire HIV during the course of a prevention study? An analysis of ethical foundation, regulation, and recent argumentation provides no basis for the obligation. We outline an alternative approach to the problem based on moral negotiation.